scholarly journals Priapism as the initial manifestation of chronic myeloid leukemia, a rare presentation

2021 ◽  
Vol 9 (7) ◽  
pp. 2102
Author(s):  
Regina De Miguel-Ibañez ◽  
Marcos Daniel Sanchez-Gonzalez ◽  
Diana Arlett Herrera-Madrid
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Myeloproliferative Neoplasm ◽  
Rare Presentation ◽  
Initial Manifestation ◽  
Ischemic Priapism ◽  
Age Of Diagnosis ◽  
Urological Emergency ◽  
Adequate Management

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with a median age of diagnosis in Mexico of 40 years. The initial manifestations are varied; however, priapism is a very rare entity associated to CML. We report the case of an 18-year-old male with an 8-hour episode of ischemic priapism managed with cavernous lavage, achieving complete flaccidity of the penis. The patient was diagnosed with CML, initiating cytoreduction with hydroxycarbamide and after having molecular confirmation, we started treatment with a tyrosine kinase inhibitor. The patient was discharged in excellent conditions, without sequelae of erectile dysfunction, all this attributed to the time of evolution, the adequate management of the urological emergency and the prompt identification and treatment of the precipitating condition.

scholarly journals INNO-406 inhibit the growth of chronic myeloid leukemia and promote its apoptosis via targeting PTEN

2020 ◽  
Author(s):  
Jiandong Sun ◽  
Yilin Wang ◽  
Lirong Sun
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Molecular Mechanism ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Myeloproliferative Neoplasm ◽  
Lyn Kinase ◽  
Apoptotic Protein ◽  
Induced Apoptosis ◽  
Kinase Inhibitory Activity

Abstract Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm. INNO-406 is a novel tyrosine kinase inhibitor (TKI) that possess specific Lyn kinase inhibitory activity with no or limited activity against other sarcoma (Src) family member kinases. The present study aimed to confirm the anti-tumor effect of INNO-406 on CML cells, and elucidate the molecular mechanism underlying its effect. Methods The cell proliferation and apoptosis were detected by MTT, western blot and flow cytometry respectively. Results As suggested by the findings, INNO-406 significantly inhibited the proliferation and induced apoptosis of CML cells. In addition, INNO-406 promoted the expression level of PETN. Rescue experiment revealed that PTEN knockdown reversed the effect of INNO-406 which indicated the correlation between INNO-406 and PTEN. Further study determined that PTEN inhibited the phosphorylation of AKT and 4EBP1 and subsequently altered the expression of apoptotic protein expressions including bax, cytochrome c (cyto-c), cleaved caspase3 and bcl-2. In vivo study further confirmed that INNO-406 inhibited the growth of CML cells in vivo by targeting PTEN. Conclusion Based on the above findings, this work extended our understanding of INNO-406 in the chemotherapy of CML and its molecular mechanism.

scholarly journals Priapism: a rare presentation in chronic myeloid leukemia

2019 ◽  
Vol 6 (6) ◽  
pp. 1937
Author(s):  
Avtar Singh Dhanju ◽  
Princy Tyagi ◽  
Sumitoj Singh Dhaliwal ◽  
Surender Paul ◽  
Rajbinder Singh ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Blood Smear ◽  
Bone Marrow Aspiration ◽  
Peripheral Blood Smear ◽  
Rare Presentation ◽  
Urological Emergency ◽  
Author Report

Priapism is a rare presenting feature of Chronic Myeloid Leukemia (CML). It is an urological emergency which requires urgent treatment to prevent long term complications, in particular erectile dysfunction. Author report a case of 18 year old male presenting with persistent painful erection of penis for around 14 hours. The patient underwent immediate irrigation and decompression of priapism in emergency and was started on cytoreductive therapy. During hospitalization, peripheral blood smear and bone marrow aspiration confirmed the diagnosis of CML.

Rare presentation and initial management of ischemic priapism in two cases of chronic myeloid leukemia

2021 ◽  
Vol 26 (3) ◽  
pp. 205
Author(s):  
AdetolaTolani Musliu ◽  
Sudi Abdullahi ◽  
YusufJamoh Bello ◽  
OlawaleAfolayan Ayodeji ◽  
AdesinaOpoola Asimiyu ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Rare Presentation ◽  
Initial Management ◽  
Ischemic Priapism

scholarly journals Chronic myeloid leukemia stem cells: targeting therapeutic implications

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Hanieh Mojtahedi ◽  
Niloufar Yazdanpanah ◽  
Nima Rezaei
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Kinase Inhibitor ◽  
Myeloproliferative Neoplasm ◽  
Therapy Resistance ◽  
Therapeutic Implications ◽  
Clinical Benefits ◽  
Survival Mechanisms

AbstractChronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as confirmed by the success of tyrosine kinase inhibitor (TKI) therapy. Despite advances in the development of more potent tyrosine kinase inhibitors, some mechanisms particularly in terms of CML leukemic stem cell (CML LSC) lead to intrinsic or acquired therapy resistance, relapse, and disease progression. In fact, the maintenance CML LSCs in patients who are resistance to TKI therapy indicates the role of CML LSCs in resistance to therapy through survival mechanisms that are not completely dependent on BCR-ABL activity. Targeting therapeutic approaches aim to eradicate CML LSCs through characterization and targeting genetic alteration and molecular pathways involving in CML LSC survival in a favorable leukemic microenvironment and resistance to apoptosis, with the hope of providing a functional cure. In other words, it is possible to develop the combination therapy of TKs with drugs targeting genes or molecules more specifically, which is required for survival mechanisms of CML LSCs, while sparing normal HSCs for clinical benefits along with TKIs.

Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era

2013 ◽  
Vol 13 (7) ◽  
pp. 755-767 ◽  
Author(s):  
Domenico Russo ◽  
Michele Malagola ◽  
Cristina Skert ◽  
Carla Filì ◽  
Cesare Bergonzi ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Elderly Patients ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor

scholarly journals Thrombotic microangiopathy in dasatinib-treated patients with chronic myeloid leukemia

2019 ◽  
Vol 4 (1-2) ◽  
pp. 41-45 ◽  
Author(s):  
Takeo Koshida ◽  
Sylvia Wu ◽  
Hitoshi Suzuki ◽  
Rimda Wanchoo ◽  
Vanesa Bijol ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Tyrosine Kinase Inhibitors ◽  
Thrombotic Microangiopathy ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Kidney Biopsy ◽  
Kinase Inhibitor ◽  
Target Effect

Dasatinib is the second-generation tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. Proteinuria has been reported with this agent. We describe two kidney biopsy–proven cases of dasatinib-induced thrombotic microangiopathy that responded to stoppage of dasatinib and using an alternate tyrosine kinase inhibitor. Certain specific tyrosine kinase inhibitors lead to endothelial injury and renal-limited thrombotic microangiopathy. Hematologists and nephrologists need to be familiar with this off-target effect of dasatinib.

Sign in / Sign up

Export Citation Format

Share Document